Workflow
四环生物(000518) - 2014 Q1 - 季度财报
JSSHJSSH(SZ:000518)2014-04-29 16:00

Financial Performance - The company's operating revenue for Q1 2014 was ¥74,755,076.02, representing a 45.82% increase compared to ¥51,263,649.93 in the same period last year[8] - Net profit attributable to shareholders was ¥12,833,227.70, a significant turnaround from a loss of ¥2,949,060.66, marking a 535.16% improvement[8] - The net profit after deducting non-recurring gains and losses was ¥12,799,165.59, up 4,007.93% from ¥311,572.46 in the previous year[8] - The basic earnings per share increased to ¥0.0125 from a loss of ¥0.0029, reflecting a 531.03% improvement[8] - The weighted average return on equity rose to 1.88%, compared to -0.4% in the same period last year, an increase of 2.28%[8] - The company reported an operating profit of CNY 15,124,626.46, a significant turnaround from a loss of CNY 1,023,360.27 in the previous year[16] Assets and Shareholder Information - Total assets at the end of the reporting period were ¥836,874,124.73, a 1.74% increase from ¥822,583,877.99 at the end of the previous year[8] - Net assets attributable to shareholders increased to ¥687,943,975.64, up 1.9% from ¥675,110,747.94 at the end of the previous year[8] - The total number of shareholders at the end of the reporting period was 172,440[11] - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., held 3.89% of the shares, amounting to 40,000,000 shares[11] Cash Flow and Expenses - The company reported a net cash flow from operating activities of -¥591,346.92, an improvement of 92.52% from -¥7,903,350.51 in the previous year[8] - Other receivables rose by 51.23% to CNY 12,655,795.16, attributed to new personal loans to sales staff[16] - Employee compensation payable decreased by 48.92% to CNY 2,091,238.53, as all outstanding wages from 2013 were paid out[16] - Tax payable increased by 65.24% to CNY 10,995,609.27, due to the accrual of corporate income tax in Q1[16] - Sales expenses surged by 94.83% to CNY 10,913,165.22, driven by increased advertising costs[16] - Capital expenditures for fixed and intangible assets increased by 2598.88% to CNY 11,151,649.66, reflecting new technology investments[16] - The net cash flow from financing activities was negative CNY 2,510,470.23, as the company repaid CNY 2,500,000 in loans[16] Legal and Project Updates - The company is facing litigation regarding the equity transfer contract with Beijing Vida Pharm Technology Co., which is still pending judgment[17] - The Xinjiang Aidi new energy project is delayed due to insufficient construction funds, with an uncertain production start date[17]